We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca is expanding its oncology product portfolio with a $6 billion development and commercialization agreement for Daiichi Sankyo’s investigational cancer treatment DS-1062. Read More
Pfizer and BioNTech began a phase 2/3 trial yesterday of one of their COVID-19 vaccine candidates, but not the one originally considered to be the most promising. Read More
Moderna has begun a much-anticipated phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 — the first phase 3 trial of a coronavirus vaccine in the U.S. Read More
Dynavax has partnered with Taiwan-based Medigen Vaccine Biologics to develop a COVID-19 vaccine candidate. The partners will evaluate Medigen’s recombinant form of the SARS-CoV2 spike protein combined with Dynavax’s CpG1018 adjuvant. Read More